Stereotactic body radiation therapy in patients with pelvic recurrence from rectal carcinoma

Mi Sook Kim, Chul Won Choi, Sung Yul Yoo, Chul Koo Cho, Young Seok Seo, Young Hoon Ji, Dong Han Lee, Dae Yong Hwang, Sun Mi Moon, Min Suk Kim, Hye Jeong Kang

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Objective: To investigate the clinical applications of stereotactic body radiation therapy (SBRT) using the CyberKnife system for pelvic recurrence from rectal cancer with a focus on survival and toxicity. Methods: Between 2002 and 2006, 23 patients with recurrent rectal cancer were treated with SBRT at our institution. The median follow-up was 31 months. Sites of recurrence were pre-sacral in seven patients and the pelvic wall in 16. SBRT doses ranged from 30 to 51 Gy (median 39 Gy) and were delivered in three fractions. Response to treatment was assessed by computed tomography. Overall and local progression-free survival and toxicities were recorded. Results: Four-year overall survival and local control rates were 24.9 and 74.3%, respectively. No prognostic factor was found to affect patient survival or local progression. One patient developed a severe radiation-related toxicity, but recovered completely after treatment. Conclusions: SBRT for pelvic recurrence was found to be comparable with other modalities with respect to overall survival and complication rates. Further studies are needed to confirm these preliminary results.

Original languageEnglish
Pages (from-to)695-700
Number of pages6
JournalJapanese Journal of Clinical Oncology
Volume38
Issue number10
DOIs
Publication statusPublished - 2008 Oct 1
Externally publishedYes

Fingerprint

Radiotherapy
Carcinoma
Recurrence
Rectal Neoplasms
Survival
Disease-Free Survival
Survival Rate
Tomography
Radiation
Therapeutics

Keywords

  • CyberKnife
  • Rectal cancer
  • Recurrence
  • Stereotactic body radiation therapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Stereotactic body radiation therapy in patients with pelvic recurrence from rectal carcinoma. / Kim, Mi Sook; Choi, Chul Won; Yoo, Sung Yul; Cho, Chul Koo; Seo, Young Seok; Ji, Young Hoon; Lee, Dong Han; Hwang, Dae Yong; Moon, Sun Mi; Kim, Min Suk; Kang, Hye Jeong.

In: Japanese Journal of Clinical Oncology, Vol. 38, No. 10, 01.10.2008, p. 695-700.

Research output: Contribution to journalArticle

Kim, MS, Choi, CW, Yoo, SY, Cho, CK, Seo, YS, Ji, YH, Lee, DH, Hwang, DY, Moon, SM, Kim, MS & Kang, HJ 2008, 'Stereotactic body radiation therapy in patients with pelvic recurrence from rectal carcinoma', Japanese Journal of Clinical Oncology, vol. 38, no. 10, pp. 695-700. https://doi.org/10.1093/jjco/hyn083
Kim, Mi Sook ; Choi, Chul Won ; Yoo, Sung Yul ; Cho, Chul Koo ; Seo, Young Seok ; Ji, Young Hoon ; Lee, Dong Han ; Hwang, Dae Yong ; Moon, Sun Mi ; Kim, Min Suk ; Kang, Hye Jeong. / Stereotactic body radiation therapy in patients with pelvic recurrence from rectal carcinoma. In: Japanese Journal of Clinical Oncology. 2008 ; Vol. 38, No. 10. pp. 695-700.
@article{079e19a00b5b4dc1892f9009b12f3255,
title = "Stereotactic body radiation therapy in patients with pelvic recurrence from rectal carcinoma",
abstract = "Objective: To investigate the clinical applications of stereotactic body radiation therapy (SBRT) using the CyberKnife system for pelvic recurrence from rectal cancer with a focus on survival and toxicity. Methods: Between 2002 and 2006, 23 patients with recurrent rectal cancer were treated with SBRT at our institution. The median follow-up was 31 months. Sites of recurrence were pre-sacral in seven patients and the pelvic wall in 16. SBRT doses ranged from 30 to 51 Gy (median 39 Gy) and were delivered in three fractions. Response to treatment was assessed by computed tomography. Overall and local progression-free survival and toxicities were recorded. Results: Four-year overall survival and local control rates were 24.9 and 74.3{\%}, respectively. No prognostic factor was found to affect patient survival or local progression. One patient developed a severe radiation-related toxicity, but recovered completely after treatment. Conclusions: SBRT for pelvic recurrence was found to be comparable with other modalities with respect to overall survival and complication rates. Further studies are needed to confirm these preliminary results.",
keywords = "CyberKnife, Rectal cancer, Recurrence, Stereotactic body radiation therapy",
author = "Kim, {Mi Sook} and Choi, {Chul Won} and Yoo, {Sung Yul} and Cho, {Chul Koo} and Seo, {Young Seok} and Ji, {Young Hoon} and Lee, {Dong Han} and Hwang, {Dae Yong} and Moon, {Sun Mi} and Kim, {Min Suk} and Kang, {Hye Jeong}",
year = "2008",
month = "10",
day = "1",
doi = "10.1093/jjco/hyn083",
language = "English",
volume = "38",
pages = "695--700",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "10",

}

TY - JOUR

T1 - Stereotactic body radiation therapy in patients with pelvic recurrence from rectal carcinoma

AU - Kim, Mi Sook

AU - Choi, Chul Won

AU - Yoo, Sung Yul

AU - Cho, Chul Koo

AU - Seo, Young Seok

AU - Ji, Young Hoon

AU - Lee, Dong Han

AU - Hwang, Dae Yong

AU - Moon, Sun Mi

AU - Kim, Min Suk

AU - Kang, Hye Jeong

PY - 2008/10/1

Y1 - 2008/10/1

N2 - Objective: To investigate the clinical applications of stereotactic body radiation therapy (SBRT) using the CyberKnife system for pelvic recurrence from rectal cancer with a focus on survival and toxicity. Methods: Between 2002 and 2006, 23 patients with recurrent rectal cancer were treated with SBRT at our institution. The median follow-up was 31 months. Sites of recurrence were pre-sacral in seven patients and the pelvic wall in 16. SBRT doses ranged from 30 to 51 Gy (median 39 Gy) and were delivered in three fractions. Response to treatment was assessed by computed tomography. Overall and local progression-free survival and toxicities were recorded. Results: Four-year overall survival and local control rates were 24.9 and 74.3%, respectively. No prognostic factor was found to affect patient survival or local progression. One patient developed a severe radiation-related toxicity, but recovered completely after treatment. Conclusions: SBRT for pelvic recurrence was found to be comparable with other modalities with respect to overall survival and complication rates. Further studies are needed to confirm these preliminary results.

AB - Objective: To investigate the clinical applications of stereotactic body radiation therapy (SBRT) using the CyberKnife system for pelvic recurrence from rectal cancer with a focus on survival and toxicity. Methods: Between 2002 and 2006, 23 patients with recurrent rectal cancer were treated with SBRT at our institution. The median follow-up was 31 months. Sites of recurrence were pre-sacral in seven patients and the pelvic wall in 16. SBRT doses ranged from 30 to 51 Gy (median 39 Gy) and were delivered in three fractions. Response to treatment was assessed by computed tomography. Overall and local progression-free survival and toxicities were recorded. Results: Four-year overall survival and local control rates were 24.9 and 74.3%, respectively. No prognostic factor was found to affect patient survival or local progression. One patient developed a severe radiation-related toxicity, but recovered completely after treatment. Conclusions: SBRT for pelvic recurrence was found to be comparable with other modalities with respect to overall survival and complication rates. Further studies are needed to confirm these preliminary results.

KW - CyberKnife

KW - Rectal cancer

KW - Recurrence

KW - Stereotactic body radiation therapy

UR - http://www.scopus.com/inward/record.url?scp=54949131317&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54949131317&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyn083

DO - 10.1093/jjco/hyn083

M3 - Article

C2 - 18723850

AN - SCOPUS:54949131317

VL - 38

SP - 695

EP - 700

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 10

ER -